TDENV PIV

Drug Profile

TDENV PIV

Alternative Names: Tetravalent dengue virus purified inactivated vaccine with alum adjuvant

Latest Information Update: 11 May 2017

Price : $50

At a glance

  • Originator Walter Reed Army Institute of Research
  • Developer GlaxoSmithKline; United States Army Medical Research and Materiel Command; Walter Reed Army Institute of Research
  • Class Dengue vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Dengue

Most Recent Events

  • 11 May 2017 Phase I development in Dengue (Prevention) in Puerto Rico (NCT01702857)
  • 11 May 2017 U.S. Army Medical Research and Materiel Command plans a phase I trial for Dengue (In volunteers, Prevention) in USA (NCT03141138)
  • 05 Apr 2017 GlaxoSmithKline withdraws a phase I trial in Dengue (prevention) prior to enrolment in USA (NCT03110952)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top